XZB(SH:603040) He Nan Ri Bao·2026-01-20 23:58Core Viewpoint - The article highlights the transformation of Wang's Group from a traditional construction and real estate company to a player in the biopharmaceutical industry, exemplified by its subsidiary, Zhiwei Pharmaceutical, which has developed innovative drugs and is advancing multiple clinical trials [1][2]. Company Overview - Zhiwei Pharmaceutical has developed a Class I innovative drug, a BTK inhibitor TM471-1, which has entered Phase II clinical trials for one indication, with several others expected to follow [1]. - The company has secured four international PCT patents covering over 30 countries and regions, showcasing its global reach and innovation capabilities [2]. Industry Development - The biopharmaceutical sector is identified as a promising and growing market, with New Xiang City being a strategic hub for this industry, housing over 140 industrial enterprises contributing significantly to the local economy [2]. - The local government has been proactive in fostering the biopharmaceutical industry through partnerships with educational institutions and the establishment of high-level platforms to support innovation [2][4]. Research and Innovation - New Xiang City is home to numerous research and development platforms, including 10 national-level and 140 provincial-level labs, which are crucial for driving advancements in the biopharmaceutical field [4]. - The city is expanding its biopharmaceutical landscape, with nearly 2,000 varieties of products, including blood products, vaccines, and antibiotics, and is leading in several medical fields [4]. Future Prospects - Companies in New Xiang are not only focusing on existing markets but are also venturing into high-end medical devices and diagnostics, indicating a shift towards more advanced healthcare solutions [3]. - The integration of academic research with industry practices is expected to enhance the innovation capacity and market competitiveness of the biopharmaceutical sector in New Xiang [4].